How is TB-500 dosed?
No trial has set a TB-500 dose. Clinics commonly give 2,000 to 5,000 mcg (2 to 5 mg) (2–5 mg) by subcutaneous injection twice a week for 4 to 6 weeks, then a lower maintenance dose of about 2,000 to 2,500 mcg (2–2.5 mg) once a week to once every two weeks. Every human trial in this family tested a different, related molecule, full-length thymosin beta-4, and this page keeps the two apart.
Topic: Reading what was actually studied under the name TB-500 versus thymosin beta-4
Audience: Anyone comparing a TB-500 dose figure against what has (and hasn’t) been studied
Reading time: 9–11 minutes
Zero completed human trials of the TB-500 fragment itself
FDA’s own July 2026 evaluation states it is “particularly concerned about the absence of human data on drug products containing” TB-500, “administered via any ROA [route of administration].” Every human trial reported on this page tested a different, full-length molecule — thymosin beta-4 — not TB-500. Every figure below reports a clinic’s published practice or a specific study — not a recommendation.
TB-500 vs. thymosin beta-4: two different molecules
TB-500 (also called the TB4 Fragment 17-23) is a synthetic 7-amino-acid peptide, sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH, reported to reproduce part of the actin-binding activity of a much larger protein. Thymosin beta-4 (Tβ4) is that larger protein — a naturally occurring 43-amino-acid peptide from the thymus gland — and it is Tβ4, not TB-500, that RegeneRx Biopharmaceuticals and other sponsors have taken into human clinical trials. The TB-500 profile covers the mechanism and broader research context; this page exists specifically to keep that distinction visible in every trial and study cited.
The schedules clinics publish come first, then the thymosin beta-4 human trials, labeled as a different molecule throughout and never as evidence for TB-500. The one study that names TB-500 in its own methods was not done in people; it is described in the references.
What dose do clinics publish?
No trial has set a TB-500 dose, so the schedules below are clinic practice, not trial results. Clinics commonly give 2,000 to 5,000 mcg (2–5 mg) by subcutaneous injection twice a week for 4 to 6 weeks, then a lower maintenance dose of about 2,000 to 2,500 mcg (2–2.5 mg) once a week to once every two weeks. One clinic describes the protocol shared online as 4,000 to 6,000 mcg (4–6 mg) a week in two injections, then 2,000 to 2,500 mcg (2–2.5 mg) once a week.
Others give it daily on 5 days of 7 from a blend vial, or weekly, without milligram figures. Courses run 4 to 8 weeks, or 6 to 12 weeks in all before the course is reassessed; one blend protocol runs a 3-month cycle followed by a 2-month break. Clinics administer it by subcutaneous injection, usually in the abdomen or the thigh, and prescribe it after a consultation, with labs at some, and follow-ups every 4 to 6 weeks. The clinics are listed in the references.
Each clinic’s protocol is set out in the TB-500 profile’s dosing table; how often clinics inject it is answered in How often is TB-500 dosed?, and the side effects clinics list, with the cases in which they avoid it, in What are the side effects of thymosin beta-4?.
The human trials — all of them thymosin beta-4, not TB-500
ClinicalTrials.gov lists six registered trials of full-length thymosin beta-4. None of them is a trial of TB-500. A registry entry that appears to describe an active, recruiting TB-500 trial (NCT07487363) is a ClinicalTrials.gov example record — its own description states it “models common ClinicalTrials.gov data elements for an interventional study” and that “the specific dose levels are protocol-defined and are not provided in this public example.” It is not a real trial and is not cited as evidence anywhere on this page.
Epidermolysis Bullosa — Topical Thymosin Beta-4
NCT00311766TERMINATED (per the registry: "Lack of patient availability and expiration of study drug" — not a safety or efficacy stop)
Design: Phase 2, randomized, double-blind, placebo-controlled trial testing topical thymosin beta-4 gel for wound healing in patients with epidermolysis bullosa.
Arms: 30 participants enrolled (actual, per the registry) before termination, randomized to placebo gel or thymosin beta-4 gel at 0.01%, 0.03%, or 0.1%, applied once daily for up to 56 days.
Pressure Ulcers — Topical Thymosin Beta-4
NCT00382174COMPLETED, with results posted directly to the registry
Design: Phase 2, double-blind, placebo-controlled, dose-escalation trial testing topical thymosin beta-4 gel for pressure ulcers.
Arms: 72 participants (18 placebo, 54 across three active-dose arms: 0.01%, 0.02%, and 0.1% thymosin beta-4 w/w), applied topically once daily for up to 84 days.
Endpoint reported: Complete wound healing at day 84: 8 of 54 (14.8%) thymosin-beta-4-treated versus 3 of 18 (16.7%) placebo — no meaningful difference, consistent with the trial sponsor's own public reporting that no dose reached statistical significance for complete healing.
Adverse events reported: Any treatment-emergent adverse event was reported by essentially all participants in both arms (18 of 18 placebo; 53 of 54 thymosin-beta-4-treated) — a general AE tally over an 84-day observation period, not a specific safety signal.
Venous Stasis Ulcers — Topical Thymosin Beta-4
NCT00832091COMPLETED
Design: Phase 2, double-blind, placebo-controlled, dose-response trial testing topical thymosin beta-4 gel for venous stasis ulcers.
Arms: 72 participants across three dose groups (18 active-drug and 6 placebo per group, per the registry's own group description), at three topical concentrations.
Acute Myocardial Infarction — Intravenous Recombinant Thymosin Beta-4 (three trials)
NCT05984134, NCT05485818, NCT07586865First two COMPLETED (N=90 and N=62 actual); third NOT YET RECRUITING (N=189 estimated)
Design: Phase 2 trials of intravenous recombinant human thymosin beta-4 (branded NL005 in the registered protocols) as an adjunct after percutaneous coronary intervention for acute myocardial infarction — an entirely different program, sponsor, molecule form, and route than the topical wound-care trials above.
Arms: NCT05984134's dose arms: 0.5 microgram/kg ("middle dose") and 1.5 microgram/kg ("high dose"), continuous IV administration for 7 days, versus placebo.
Outside the registry list above, a published phase 1 study gave 40 healthy volunteers full-length thymosin beta-4 into a vein at 42,000, 140,000, 420,000 or 1,260,000 mcg (42, 140, 420 or 1,260 mg) (42–1,260 mg), once and then daily for 14 days. It was well tolerated, with no dose-limiting toxicity or serious adverse events, and the half-life rose with dose. It is a record of the full-length protein, not of TB-500.
None of the clinic schedules comes from a study. The thymosin beta-4 human trials used a topical percentage gel (0.01–0.1% w/w), a microgram-per-kilogram intravenous infusion, or, in the phase 1 safety study, 42,000–1,260,000 mcg (42–1,260 mg) into a vein — none of them a subcutaneous injection of the fragment. No published source derives the clinic schedules from those trials.
Regulatory position: FDA’s own TB-500 evaluation, the PCAC vote and HHS’s draft Enforcement Discretion Policy
FDA’s own July 2026 staff evaluation weighs against 503A eligibility; the PCAC’s public vote recommends the opposite, non-bindingly.
In its July 2026 Pharmacy Compounding Advisory Committee briefing document for TB-500, FDA states “there is a lack of clinical and nonclinical safety information on the use of TB-500 (free base) and TB-500 acetate,” and that it “is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA.” The document’s conclusion states that “a balancing of the criteria weighs against TB-500 (free base) and TB-500 acetate being placed” on the 503A Bulks List, citing the same characterization and immunogenicity concerns found for BPC-157. TB-500 also appears in FDA’s 503A “bulk drug substances nominated but withdrawn” table, not the active Category 2 list.
TB-500 was one of seven substances on the agenda of the July 23–24, 2026 Pharmacy Compounding Advisory Committee, the same meeting that voted on BPC-157 (see the BPC-157 guide). The committee voted to recommend TB-500 for the 503A Bulks List — against FDA staff’s own recommendation — according to ABC News (reference 19). A committee vote is a recommendation to FDA, not a change in status.
HHS’s draft Enforcement Discretion Policy of October 30, 2026 lists TB-500 among the six peptides in its Appendix A, and its Appendix B covers TB-500 acetate in subcutaneous or intramuscular injectable dosage forms only. HHS states that it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with a peptide in Appendix A while the 503A bulks list is developed through rulemaking, and that the policy is not binding on HHS or the public. Appendix A is a separate instrument from FDA’s withdrawn-nominations table, and it is not FDA approval or a 503A listing; its conditions are set out in Prof. Peptide’s summary of the draft Enforcement Discretion Policy.
Research-grade TB-500, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither an approved product nor a verified lawfully compounded one under the current regulatory position above. It is sold labeled for laboratory research use, not for human administration, and it is not dispensed against a prescription. Clinics that prescribe TB-500 commonly describe dispensing it on prescription through a licensed 503A compounding pharmacy, and call that position contested since TB-500’s 2024 removal from 503B bulk-compounding eligibility.
FAQ
Has TB-500 been tested in a human trial?
Is TB-500 the same thing as thymosin beta-4?
What did the thymosin beta-4 trials actually test?
What dose was used in the pressure ulcer trial?
Has any study tested TB-500 itself?
Do clinics publish a TB-500 dosing schedule?
References
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822–837. PMID 42542926. The one study that names TB-500 in its own methods: male Sprague-Dawley rats given TB-500 (“synthetic thymosin beta-4”) at 60 microgram/kg/day into the abdominal cavity for 4 weeks after Achilles tendon repair; TB-500 alone raised maximum load to failure (p<0.05) and lowered Bonar and Movin scores (p=0.016, p=0.017), and adding BPC-157 did not do better than either alone. An animal dose; not converted to a human figure. https://pubmed.ncbi.nlm.nih.gov/42542926/
- ClinicalTrials.gov. A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa, NCT00311766. https://clinicaltrials.gov/study/NCT00311766
- ClinicalTrials.gov. Study of Thymosin Beta 4 in Patients With Pressure Ulcers, NCT00382174. https://clinicaltrials.gov/study/NCT00382174
- ClinicalTrials.gov. Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers, NCT00832091. https://clinicaltrials.gov/study/NCT00832091
- ClinicalTrials.gov. Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction, NCT05984134. https://clinicaltrials.gov/study/NCT05984134
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026 — Evaluation of TB-500 Bulk Drug Substances (evaluation memo dated May 15, 2026). Re-read November 6, 2026. https://www.fda.gov/media/193349/download
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026; TB-500 listed under “nominated but withdrawn”. Re-read November 6, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Beverly Hills Rejuvenation Center. TB-500 Dosage Guide: Complete Protocol for Safe Administration (bhrcenter.com). Read October 25, 2026, re-read November 6, 2026; cited for its own published schedule (2–2.5 mg twice a week for 4–6 weeks, then every 1–2 weeks), site and course length only. https://www.bhrcenter.com/tb-500-dosage-guide-complete-protocol-for-safe-administration/
- Dr. Patrick Taylor / PeptideWise. The Wolverine Stack: BPC-157 + TB-500 Recovery Guide (drpattaylor.com). Read October 25, 2026, re-read November 6, 2026; cited for its own published combined schedule (2–5 mg twice a week for 4–6 weeks, then 2 mg once a week) only. https://www.drpattaylor.com/learn/wolverine-stack-bpc-157-tb-500
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223–229. PMID 20536472. Four cohorts of 10 given 42, 140, 420 or 1,260 mg of full-length thymosin beta-4 into a vein, once and then daily for 14 days; well tolerated, no dose-limiting toxicity, half-life rising with dose. Abstract re-read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/20536472/
- Pru (joinpru.com). TB-500 dosage. Updated July 9, 2026; read November 6, 2026. Cited for the two-stage protocol it describes as shared online (about 4–6 mg a week in two subcutaneous injections for 4–6 weeks, then roughly 2–2.5 mg once a week) and the abdomen as the common site. https://joinpru.com/blog/tb-500-dosage
- Perfect B Aesthetic Medicine, Doral, Florida (perfectb.com). TB-500 dosage and 3-month cycle. Read November 3 and 6, 2026. Cited for its blend protocol (daily, five days on and two off, a 3-month cycle, then a 2-month break) and its 503A dispensing statement only. https://www.perfectb.com/?p=22197
- Menscape, Bangkok (menscapeclinic.com). TB-500. Read November 3 and 6, 2026. Cited for its weekly schedule for 4 to 8 weeks and follow-ups every 4 to 6 weeks only. https://www.menscapeclinic.com/services/peptide/tb-500
- Moonshot Medical and Performance, Park Ridge, Illinois (moonshotmp.com). TB-500. Read November 3 and 6, 2026. Cited for its course (6–12 weeks in all, then reassessed), the belly or thigh as sites, and its statement that 503A dispensing since TB-500's 2024 removal from 503B eligibility is a contested legal position. https://moonshotmp.com/learn/tb-500/
- Defy Medical (defymedical.com). TB-500: the peptide behind wound healing and tissue repair. Read November 5 and 6, 2026. Cited for its prescribing after a consultation and comprehensive labs. https://www.defymedical.com/blog/tb-500-the-peptide-behind-wound-healing-and-tissue-repair/
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, July 23–24, 2026: final agenda. Read November 6, 2026. TB-500-related bulk drug substances (TB-500 free base and TB-500 acetate) are on the agenda for the 503A bulks list. https://www.fda.gov/media/193771/download
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register, October 30, 2026, 91 FR 68526 (FR Doc. 2026-22192). Read November 6, 2026: a draft, interim policy; HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding with a peptide in Appendix A; not binding on HHS or the public. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A and Appendix B. PDF dated October 28, 2026; read in full October 31, 2026 (Prof. Peptide's reading; the PDF refused an automated read on November 6, 2026). Appendix A lists BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500; Appendix B covers TB-500 acetate in subcutaneous or intramuscular injectable dosage forms. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- Dr. Yonathan Daniel, ABC News. FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next? Published July 24, 2026; read November 12, 2026. Cited for the committee's recommendation of TB-500: over the two-day hearing it voted to recommend that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to an approved list of ingredients that specialty pharmacies can use; the article gives no tally. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- TB-500TB-500 in people: never studied as the fragment itself; what full-length thymosin beta-4 trials found, the doses clinics publish, reported side effects, FDA and WADA…
- Survodutide Dosage: Phase 3 Trial Doses and What Clinics ReportSurvodutide dosage: the 3,600 and 6,000 mcg (3.6 and 6 mg) weekly doses of its phase 3 SYNCHRONIZE trials, how the dose was raised, side effects at each dose, what…
- TB-500 Calculator: Dosage & ReconstitutionTB-500 reconstitution and dosage math — vial size, BAC water and syringe units, worked for the sizes vendors actually sell.
- How Is Tesamorelin Dosed? The Egrifta Label, Read DirectlyTesamorelin is FDA-approved as Egrifta WR and Egrifta SV for HIV-associated lipodystrophy — this page reads both current labels' dosing directly, the Phase 3 trials…
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
